Yangzhou Sanyao Pharmaceutical Co. Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation salbutamol tartrate inhalation aerosol (0.045 mg/INH*2 times) and the reference preparation "Xopenex Hfa®" (0.045 mg/INH*2 times) in healthy subjects after oral inhalation on an empty stomach, and to evaluate the bioequivalence of the salbutamol tartrate inhalation aerosol after oral inhalation on an empty stomach. The secondary purpose of the study is to study the safety of the test preparation salbutamol tartrate inhalation aerosol and the reference preparation "Xopenex Hfa®" in healthy subjects.

Main study purpose: This study aims to investigate the pharmacokinetic characteristics of avanafil tablets (100 mg) produced by Yangzhou Sanyao Pharmaceutical Co., Ltd. and avanafil tablets (Spedra, 100 mg) produced by Menarini-Von Heyden GmbH in healthy male subjects under the conditions of single oral administration on an empty stomach and after a meal, with pharmacokinetic parameters as the endpoint indicators, and to evaluate the bioequivalence of the two preparations. Secondary study purpose: Evaluate the safety of avanafil tablets (100 mg) produced by Yangzhou Sanyao Pharmaceutical Co., Ltd. under the conditions of single oral administration on an empty stomach and after a meal.

The purpose of this study is to use Ambroxol Hydrochloride Tablets provided by Yangzhou Sanyao Pharmaceutical Co., Ltd. as the test preparation, and Ambroxol Hydrochloride Tablets produced by Boehringer Ingelheim France as the reference preparation for human bioequivalence testing according to the relevant provisions of bioequivalence testing, and evaluate the average bioequivalence of the two preparations to provide a theoretical basis for clinical safety and rational drug use. Observe the safety of the test preparation Ambroxol Hydrochloride Tablets and the reference preparation Surbronc ® in healthy subjects.